In contrast, tumor volumes were significantly reduced in all groups that received either cisplatin (1000.8±72.6 mm3, p<0.001), cAT-MSC-Mock (777.4±84.0 mm3, p<0.001), cAT-MSC-IFN-β (421.1±102.1 mm3, p<0.001), or both cisplatin and cAT-MSC-IFN-β cells (157.7±98.7 mm3, p<0.001), in comparison with mice that received PBS as a control (Figure 7A and 7B). This evidence concerns the gene IFNB1 and neoplasm.